|
Navigation:
Home
Up
About this Site
Advanced Search
Feedback
Links
News
Site Map
3D model of DHA
| |
AD Review References for 2004:
(2004). "Estrogen and progestogen therapy in postmenopausal women."
Fertil Steril 81(1): 231-41.
Abe, K. (2004). "[Possibility of gene and restorative therapies for
dementia]." Nippon Rinsho 62 Suppl 4: 229-33.
Agorogiannis, E. I., G. I. Agorogiannis, et al. (2004). "Protein misfolding
in neurodegenerative diseases." Neuropathol Appl Neurobiol 30(3):
215-24.
Algotsson, A. and B. Winblad (2004). "Patients with Alzheimer's disease may
be particularly susceptible to adverse effects of statins." Dement
Geriatr Cogn Disord 17(3): 109-16.
Allgaier, C. and T. Arendt (2004). "[Galantamine, an acetylcholinesterase
inhibitor with various actions]." Med Monatsschr Pharm 27(7):
223-7.
Alonso, M. and A. Martinez (2004). "GSK-3 inhibitors: discoveries and
developments." Curr Med Chem 11(6): 755-63.
Alperovitch, A., M. Schwarzinger, et al. (2004). "[Towards a prevention of
dementia?]." Rev Neurol (Paris) 160(2): 256-60.
Amieva, H., L. H. Phillips, et al. (2004). "Inhibitory functioning in
Alzheimer's disease." Brain 127(Pt 5): 949-64.
Amos, J. and W. Grody (2004). "Development and integration of molecular
genetic tests into clinical practice: the US experience." Expert Rev Mol
Diagn 4(4): 465-77.
Ando, K. (2004). "[Neuropsychopharmacological profile of nicotine]."
Nihon Shinkei Seishin Yakurigaku Zasshi 24(2): 55-9.
Ansari, R. R. (2004). "Ocular static and dynamic light scattering: a
noninvasive diagnostic tool for eye research and clinical practice." J
Biomed Opt 9(1): 22-37.
Asada, T. (2004). "[Non-pharmacological therapy for Alzheimer's disease]."
Nippon Rinsho 62 Suppl: 72-5.
Asanuma, M., I. Miyazaki, et al. (2004). "Neuroprotective effects of
nonsteroidal anti-inflammatory drugs on neurodegenerative diseases." Curr
Pharm Des 10(6): 695-700.
Ashford, J. W. (2004). "APOE genotype effects on Alzheimer's disease onset
and epidemiology." J Mol Neurosci 23(3): 157-65.
Avila, C., M. A. Parcet, et al. (2004). "[Memory evaluation using functional
magnetic resonance: applications in preoperative patients and in Alzheimer s
disease]." Rev Neurol 38(3): 284-91.
Avila, J., J. J. Lucas, et al. (2004). "Role of tau protein in both
physiological and pathological conditions." Physiol Rev 84(2):
361-84.
Baghdasarian, S. B., H. Jneid, et al. (2004). "Association of dyslipidemia
and effects of statins on nonmacrovascular diseases." Clin Ther
26(3):
337-51.
Balardy, L., P. J. Ousset, et al. (2004). "[Clinical aspects of dementia and
specificity of Alzheimer's disease]." Soins(685): 30-5.
Ballard, C. G. (2004). "Definition and diagnosis of dementia with Lewy
bodies." Dement Geriatr Cogn Disord 17 Suppl 1: 15-24.
Barnham, K. J., C. L. Masters, et al. (2004). "Neurodegenerative diseases
and oxidative stress." Nat Rev Drug Discov 3(3): 205-14.
Bartzokis, G. (2004). "Age-related myelin breakdown: a developmental model
of cognitive decline and Alzheimer's disease." Neurobiol Aging
25(1):
5-18; author reply 49-62.
Baskys, A. (2004). "Lewy body dementia: the litmus test for neuroleptic
sensitivity and extrapyramidal symptoms." J Clin Psychiatry 65
Suppl 11: 16-22.
Bateman, D. A. and A. Chakrabartty (2004). "Interactions of Alzheimer
amyloid peptides with cultured cells and brain tissue, and their biological
consequences." Biopolymers 76(1): 4-14.
Benveniste, E. N., V. T. Nguyen, et al. (2004). "Molecular regulation of
CD40 gene expression in macrophages and microglia." Brain Behav Immun
18(1): 7-12.
Bertoli-Avella, A. M., B. A. Oostra, et al. (2004). "Chasing genes in
Alzheimer's and Parkinson's disease." Hum Genet 114(5):
413-38.
Bhat, R. V., S. L. Budd Haeberlein, et al. (2004). "Glycogen synthase kinase
3: a drug target for CNS therapies." J Neurochem 89(6):
1313-7.
Birks, J. and G. G. Wilcock (2004). "Velnacrine for Alzheimer's disease."
Cochrane Database Syst Rev(2): CD004748.
Birnbaum, S. G., A. W. Varga, et al. (2004). "Structure and function of
Kv4-family transient potassium channels." Physiol Rev 84(3):
803-33.
Blake, A. D., A. C. Badway, et al. (2004). "Delineating somatostatin's
neuronal actions." Curr Drug Targets CNS Neurol Disord 3(2):
153-60.
Bleich, S., D. Degner, et al. (2004). "Homocysteine as a neurotoxin in
chronic alcoholism." Prog Neuropsychopharmacol Biol Psychiatry
28(3):
453-64.
Blesch, A. and M. H. Tuszynski (2004). "Gene therapy and cell
transplantation for Alzheimer's disease and spinal cord injury." Yonsei
Med J 45 Suppl: 28-31.
Bliwise, D. L. (2004). "Sleep disorders in Alzheimer's disease and other
dementias." Clin Cornerstone 6 Suppl 1A: S16-28.
Boje, K. M. (2004). "Nitric oxide neurotoxicity in neurodegenerative
diseases." Front Biosci 9: 763-76.
Bonfils, P., D. Malinvaud, et al. (2004). "[Olfactory disorders]."
Ann
Otolaryngol Chir Cervicofac 121(2): 67-74.
Bossy-Wetzel, E., R. Schwarzenbacher, et al. (2004). "Molecular pathways to
neurodegeneration." Nat Med 10 Suppl: S2-9.
Bourre, J. M. (2004). "Roles of unsaturated fatty acids (especially omega-3
fatty acids) in the brain at various ages and during ageing." J Nutr
Health Aging 8(3): 163-74.
Boyle, P. A. (2004). "Assessing and predicting functional impairment in
Alzheimer's disease: the emerging role of frontal system dysfunction."
Curr Psychiatry Rep 6(1): 20-4.
Boyle, P. A. and P. F. Malloy (2004). "Treating apathy in Alzheimer's
disease." Dement Geriatr Cogn Disord 17(1-2): 91-9.
Braekhus, A. and K. Engedal (2004). "[Vascular dementia--an ill-defined
concept]." Tidsskr Nor Laegeforen 124(8): 1097-9.
Brew, B. J. (2004). "Evidence for a change in AIDS dementia complex in the
era of highly active antiretroviral therapy and the possibility of new forms
of AIDS dementia complex." Aids 18 Suppl 1: S75-8.
Brinton, R. D. (2004). "Impact of estrogen therapy on Alzheimer's disease: a
fork in the road?" CNS Drugs 18(7): 405-22.
Broytman, O. and J. S. Malter (2004). "Anti-Abeta: The good, the bad, and
the unforeseen." J Neurosci Res 75(3): 301-6.
Bsoul, S. A. and G. T. Terezhalmy (2004). "Vitamin C in health and disease."
J Contemp Dent Pract 5(2): 1-13.
Bugiani, O. (2004). "A beta-related cerebral amyloid angiopathy."
Neurol
Sci 25 Suppl 1: S1-2.
Bullock, R. (2004). "Future directions in the treatment of Alzheimer's
disease." Expert Opin Investig Drugs 13(4): 303-14.
Bullock, R. (2004). "Cholinesterase inhibitors and vascular dementia:
another string to their bow?" CNS Drugs 18(2): 79-92.
Burke, W. J., S. W. Li, et al. (2004). "Neurotoxicity of MAO metabolites of
catecholamine neurotransmitters: role in neurodegenerative diseases."
Neurotoxicology 25(1-2): 101-15.
Bush, A. and N. Beail (2004). "Risk factors for dementia in people with down
syndrome: issues in assessment and diagnosis." Am J Ment Retard
109(2): 83-97.
Bush, A. I. and D. Strozyk (2004). "Serum copper: a biomarker for Alzheimer
disease?" Arch Neurol 61(5): 631-2.
Butterfield, D. A. (2004). "Proteomics: a new approach to investigate
oxidative stress in Alzheimer's disease brain." Brain Res 1000(1-2):
1-7.
Butterfield, D. A. and A. I. Bush (2004). "Alzheimer's amyloid beta-peptide
(1-42): involvement of methionine residue 35 in the oxidative stress and
neurotoxicity properties of this peptide." Neurobiol Aging 25(5):
563-8.
Candore, G., C. R. Balistreri, et al. (2004). "Major histocompatibility
complex and sporadic Alzheimer's disease: a critical reappraisal." Exp
Gerontol 39(4): 645-52.
Canevari, L., A. Y. Abramov, et al. (2004). "Toxicity of amyloid beta
peptide: tales of calcium, mitochondria, and oxidative stress." Neurochem
Res 29(3): 637-50.
Carini, M., G. Aldini, et al. (2004). "Mass spectrometry for detection of
4-hydroxy-trans-2-nonenal (HNE) adducts with peptides and proteins." Mass
Spectrom Rev 23(4): 281-305.
Casanova Sotolongo, P., P. Casanova Carrillo, et al. (2004). "[Memory. An
introduction to the study of the cognitive disorders in normal and
pathological aging]." Rev Neurol 38(5): 469-72.
Casserly, I. and E. Topol (2004). "Convergence of atherosclerosis and
Alzheimer's disease: inflammation, cholesterol, and misfolded proteins."
Lancet 363(9415): 1139-46.
Castellani, R. J., G. Perry, et al. (2004). "Prion disease and Alzheimer's
disease: pathogenic overlap." Acta Neurobiol Exp (Wars) 64(1):
11-7.
Castellani, R. J., M. A. Smith, et al. (2004). "Cerebral amyloid angiopathy:
major contributor or decorative response to Alzheimer's disease
pathogenesis." Neurobiol Aging 25(5): 599-602; discussion
603-4.
Chang, C. Y. and D. H. Silverman (2004). "Accuracy of early diagnosis and
its impact on the management and course of Alzheimer's disease." Expert
Rev Mol Diagn 4(1): 63-9.
Chartier-Harlin, M. C., L. Araria-Goumidi, et al. (2004). "[Genetic
complexity of Alzheimer's disease]." Rev Neurol (Paris) 160(2):
251-5.
Cheung, Z. H. and N. Y. Ip (2004). "Cdk5: mediator of neuronal death and
survival." Neurosci Lett 361(1-3): 47-51.
Citron, M. (2004). "Beta-secretase inhibition for the treatment of
Alzheimer's disease--promise and challenge." Trends Pharmacol Sci
25(2): 92-7.
Collins, S. J., V. A. Lawson, et al. (2004). "Transmissible spongiform
encephalopathies." Lancet 363(9402): 51-61.
Conant, R. and A. G. Schauss (2004). "Therapeutic applications of citicoline
for stroke and cognitive dysfunction in the elderly: a review of the
literature." Altern Med Rev 9(1): 17-31.
Coruzzi, G., A. Menozzi, et al. (2004). "Novel non-steroidal
anti-inflammatory drugs: what we have learned from animal studies." Curr
Drug Targets Inflamm Allergy 3(1): 43-61.
Craft, S. and G. S. Watson (2004). "Insulin and neurodegenerative disease:
shared and specific mechanisms." Lancet Neurol 3(3): 169-78.
Cribbs, D. H., W. W. Poon, et al. (2004). "Caspase-mediated degeneration in
Alzheimer's disease." Am J Pathol 165(2): 353-5.
Crutcher, K. A. (2004). "Apolipoprotein E is a prime suspect, not just an
accomplice, in Alzheimer's disease." J Mol Neurosci 23(3):
181-8.
Cummings, J. L. (2004). "Alzheimer's disease." N Engl J Med
351(1):
56-67.
da Cruz e Silva, O. A., M. Fardilha, et al. (2004). "Signal transduction
therapeutics: relevance for Alzheimer's disease." J Mol Neurosci
23(1-2): 123-42.
D'Andrea, M. R., G. M. Cole, et al. (2004). "The microglial phagocytic role
with specific plaque types in the Alzheimer disease brain." Neurobiol
Aging 25(5): 675-83.
Davis, H. S. and K. Rockwood (2004). "Conceptualization of mild cognitive
impairment: a review." Int J Geriatr Psychiatry 19(4): 313-9.
de la Torre, J. C. (2004). "Is Alzheimer's disease a neurodegenerative or a
vascular disorder? Data, dogma, and dialectics." Lancet Neurol
3(3):
184-90.
de Leeuw, F. E. and J. van Gijn (2004). "[Vascular dementia]."
Ned
Tijdschr Geneeskd 148(24): 1181-6.
de Mendonca, A., M. Guerreiro, et al. (2004). "Mild cognitive impairment:
focus on diagnosis." J Mol Neurosci 23(1-2): 143-8.
Dejaegere, T. and B. de Strooper (2004). "[Secretases as therapeutic targets
for the treatment of Alzheimer's disease]." Verh K Acad Geneeskd Belg
66(1): 29-58; discussion 58-9.
DeMattos, R. B. (2004). "Apolipoprotein E dose-dependent modulation of
beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease."
J Mol Neurosci 23(3): 255-62.
Dickson, D. W. (2004). "Apoptotic mechanisms in Alzheimer neurofibrillary
degeneration: cause or effect?" J Clin Invest 114(1): 23-7.
Dlamini, Z., Z. Mbita, et al. (2004). "Genealogy, expression, and molecular
mechanisms in apoptosis." Pharmacol Ther 101(1): 1-15.
Dobson, J. (2004). "Magnetic iron compounds in neurological disorders."
Ann N Y Acad Sci 1012: 183-92.
Doggrell, S. A. (2004). "The potential of activation of somatostatinergic
neurotransmission with FK960 in Alzheimer's disease." Expert Opin
Investig Drugs 13(1): 69-72.
Dogrukol-Ak, D., F. Tore, et al. (2004). "Passage of VIP/PACAP/secretin
family across the blood-brain barrier: therapeutic effects." Curr Pharm
Des 10(12): 1325-40.
Doraiswamy, P. M. and A. E. Finefrock (2004). "Metals in our minds:
therapeutic implications for neurodegenerative disorders." Lancet Neurol
3(7): 431-4.
Duda, J. E. (2004). "Pathology and neurotransmitter abnormalities of
dementia with Lewy bodies." Dement Geriatr Cogn Disord 17 Suppl 1:
3-14.
Eikelenboom, P. and W. A. van Gool (2004). "Neuroinflammatory perspectives
on the two faces of Alzheimer's disease." J Neural Transm 111(3):
281-94.
Eisfeld, I. S. (2004). "[Semantic dementia: clinical profile and
cognitive-neuropsychological relevance]." Fortschr Neurol Psychiatr
72(7): 383-96.
Ekshyyan, O. and T. Y. Aw (2004). "Apoptosis in acute and chronic
neurological disorders." Front Biosci 9: 1567-76.
Esteban, J. A. (2004). "Living with the enemy: a physiological role for the
beta-amyloid peptide." Trends Neurosci 27(1): 1-3.
Farlow, M. R. (2004). "NMDA receptor antagonists. A new therapeutic approach
for Alzheimer's disease." Geriatrics 59(6): 22-7.
Fendyur, A., I. Kaiserman, et al. (2004). "The burst of mitochondrial
diseases: neurons and calcium." Isr Med Assoc J 6(6): 356-9.
Finch, C. E. and C. B. Stanford (2004). "Meat-adaptive genes and the
evolution of slower aging in humans." Q Rev Biol 79(1): 3-50.
Forman, M. S. (2004). "Genotype-phenotype correlations in FTDP-17: does form
follow function?" Exp Neurol 187(2): 229-34.
Fountoulakis, K. N., G. St Kaprinis, et al. (2004). "Is there a role for
pupillometry in the diagnostic approach of Alzheimer's disease? a review of
the data." J Am Geriatr Soc 52(1): 166-8.
Fountoulakis, M. (2004). "Application of proteomics technologies in the
investigation of the brain." Mass Spectrom Rev 23(4): 231-58.
Fratiglioni, L., S. Paillard-Borg, et al. (2004). "An active and socially
integrated lifestyle in late life might protect against dementia." Lancet
Neurol 3(6): 343-53.
Frolich, L., J. Fox, et al. (2004). "Targets of antidementive therapy: drugs
with a specific pharmacological mechanism of action." Curr Pharm Des
10(3): 223-9.
Gallarda, T. and H. Loo (2004). "[Memantine (Ebixa): a new therapeutic
strategy for the treatment of moderate to severe forms of Alzheimer's
disease]." Encephale 30(1): 69-79.
Gandy, S. (2004). "Cerebral Abeta amyloidosis and postmenopausal hormone
deficiency: roles in the genesis of Alzheimer's disease." Hum Pathol
35(3): 271-4.
Garcia, T. and D. Jay (2004). "[Phosphorylation of tau and Alzheimer's
disease]." Gac Med Mex 140(3): 329-33.
Gauthier, S. (2004). "[Treatment of Alzheimer's disease: general
methodological aspects]." Rev Neurol (Paris) 160(2): 261-4.
Geerts, H. (2004). "[The virtual synapse what is its contribution to
understanding cholinergic neural transmission?]." Therapie 59(1):
21-3.
Geerts, H. (2004). "NC-531 (Neurochem)." Curr Opin Investig Drugs
5(1): 95-100.
Gerlai, R. and J. Gerlai (2004). "Autism: a target of pharmacotherapies?"
Drug Discov Today 9(8): 366-74.
Gertz, H. J. and M. Kiefer (2004). "Review about Ginkgo biloba special
extract EGb 761 (Ginkgo)." Curr Pharm Des 10(3): 261-4.
Ginsberg, S. D., I. Elarova, et al. (2004). "Single-cell gene expression
analysis: implications for neurodegenerative and neuropsychiatric
disorders." Neurochem Res 29(6): 1053-64.
Gladkevich, A., H. F. Kauffman, et al. (2004). "Lymphocytes as a neural
probe: potential for studying psychiatric disorders." Prog
Neuropsychopharmacol Biol Psychiatry 28(3): 559-76.
Gomez-Ramos, A., M. A. Smith, et al. (2004). "Tau phosphorylation and
assembly." Acta Neurobiol Exp (Wars) 64(1): 33-9.
Gould, T. D., C. A. Zarate, et al. (2004). "Glycogen synthase kinase-3: a
target for novel bipolar disorder treatments." J Clin Psychiatry
65(1): 10-21.
Green, B. (2004). "Focus on aripiprazole."
Curr Med Res Opin 20(2):
207-13.
Grunblatt, E. (2004). "The benefits of microarrays as tools for studying
neuropsychiatric disorders." Drugs Today (Barc) 40(2): 147-56.
Gsell, W., G. Jungkunz, et al. (2004). "Functional neurochemistry of
Alzheimer's disease." Curr Pharm Des 10(3): 265-93.
Haan, M. N. and R. Wallace (2004). "Can dementia be prevented? Brain aging
in a population-based context." Annu Rev Public Health 25:
1-24.
Hakii, Y. and Y. Kuroiwa (2004). "[Vascular dementia--a diagnosis and
diacrisis of similar disorders]." Nippon Rinsho 62 Suppl:
23-7.
Hamel, E. (2004). "Cholinergic modulation of the cortical microvascular
bed." Prog Brain Res 145: 171-8.
Hampel, H., A. Mitchell, et al. (2004). "Core biological marker candidates
of Alzheimer's disease - perspectives for diagnosis, prediction of outcome
and reflection of biological activity." J Neural Transm 111(3):
247-72.
Hara, H. (2004). "[Vaccine therapy for Alzheimer's disease]."
Nippon
Rinsho 62 Suppl 4: 254-8.
Hardy, J. (2004). "Toward Alzheimer therapies based on genetic knowledge."
Annu Rev Med 55: 15-25.
Hawkes, C. and S. Kar (2004). "The insulin-like growth
factor-II/mannose-6-phosphate receptor: structure, distribution and function
in the central nervous system." Brain Res Brain Res Rev 44(2-3):
117-40.
Head, E. and I. T. Lott (2004). "Down syndrome and beta-amyloid deposition."
Curr Opin Neurol 17(2): 95-100.
Heales, S. J., A. A. Lam, et al. (2004). "Neurodegeneration or
neuroprotection: the pivotal role of astrocytes." Neurochem Res
29(3):
513-9.
Heinrich, M. and H. Lee Teoh (2004). "Galanthamine from snowdrop--the
development of a modern drug against Alzheimer's disease from local
Caucasian knowledge." J Ethnopharmacol 92(2-3): 147-62.
Henderson, V. W. (2004). "Hormone therapy and Alzheimer's disease: benefit
or harm?" Expert Opin Pharmacother 5(2): 389-406.
Heppner, F. L., S. Gandy, et al. (2004). "Current concepts and future
prospects for Alzheimer disease vaccines." Alzheimer Dis Assoc Disord
18(1): 38-43.
Hertz, L., Y. Chen, et al. (2004). "Astrocytic adrenoceptors: a major drug
target in neurological and psychiatric disorders?" Curr Drug Targets CNS
Neurol Disord 3(3): 239-67.
Hirai, S. (2004). "[Anti-dementia drugs--current trend]."
Nippon Ronen
Igakkai Zasshi 41(3): 275-7.
Hirouchi, M. (2004). "[Current status and perspectives on the development of
therapeutic agents for Alzheimer's disease]." Nippon Yakurigaku Zasshi
123(6): 421-7.
Hogg, R. C. and D. Bertrand (2004). "Nicotinic acetylcholine receptors as
drug targets." Curr Drug Targets CNS Neurol Disord 3(2):
123-30.
Holtzman, D. M. (2004). "In vivo effects of ApoE and clusterin on
amyloid-beta metabolism and neuropathology." J Mol Neurosci 23(3):
247-54.
Honda, K., G. Casadesus, et al. (2004). "Oxidative stress and redox-active
iron in Alzheimer's disease." Ann N Y Acad Sci 1012: 179-82.
Hoshi, M. (2004). "[Amylospheroid and the 'morphometabolism' disease
(conformational disease)]." Tanpakushitsu Kakusan Koso 49(7
Suppl): 1098-100.
Hou, C. E., D. Carlin, et al. (2004). "Non-Alzheimer's disease dementias:
anatomic, clinical, and molecular correlates." Can J Psychiatry
49(3):
164-71.
Hovinga, C. A. (2004). "Valrocemide (Teva/Acorda)."
Curr Opin Investig
Drugs 5(1): 101-6.
Hoyer, S. (2004). "Causes and consequences of disturbances of cerebral
glucose metabolism in sporadic Alzheimer disease: therapeutic implications."
Adv Exp Med Biol 541: 135-52.
Huang, X., R. D. Moir, et al. (2004). "Redox-active metals, oxidative
stress, and Alzheimer's disease pathology." Ann N Y Acad Sci 1012:
153-63.
Huang, Y., K. H. Weisgraber, et al. (2004). "Apolipoprotein E: diversity of
cellular origins, structural and biophysical properties, and effects in
Alzheimer's disease." J Mol Neurosci 23(3): 189-204.
Iadecola, C. (2004). "Neurovascular regulation in the normal brain and in
Alzheimer's disease." Nat Rev Neurosci 5(5): 347-60.
Ibach, B. and E. Haen (2004). "Acetylcholinesterase inhibition in
Alzheimer's Disease." Curr Pharm Des 10(3): 231-51.
Itzhaki, R. F., M. A. Wozniak, et al. (2004). "Infiltration of the brain by
pathogens causes Alzheimer's disease." Neurobiol Aging 25(5):
619-27.
Iwatsubo, T. (2004). "[Alzheimer's disease: focus on beta-amyloid and
gamma-secretase]." Tanpakushitsu Kakusan Koso 49(7 Suppl):
1086-90.
Jaeger, L. B. and W. A. Banks (2004). "Antisense therapeutics and the
treatment of CNS disease." Front Biosci 9: 1720-7.
Jeong, J. (2004). "EEG dynamics in patients with Alzheimer's disease."
Clin Neurophysiol 115(7): 1490-505.
Johansson, J., T. E. Weaver, et al. (2004). "Proteolytic generation and
aggregation of peptides from transmembrane regions: lung surfactant protein
C and amyloid beta-peptide." Cell Mol Life Sci 61(3): 326-35.
Jones, L. B. (2004). "Loss of spines and neuropil." Int Rev Neurobiol
59: 1-18.
Jope, R. S. and G. V. Johnson (2004). "The glamour and gloom of glycogen
synthase kinase-3." Trends Biochem Sci 29(2): 95-102.
Kadomatsu, K. and T. Muramatsu (2004). "Midkine and pleiotrophin in neural
development and cancer." Cancer Lett 204(2): 127-43.
Kar, S. and R. Quirion (2004). "Amyloid beta peptides and central
cholinergic neurons: functional interrelationship and relevance to
Alzheimer's disease pathology." Prog Brain Res 145: 261-74.
Karkos, J. (2004). "[Immunotherapy of Alzheimer's disease. Results of
experimental investigations and treatment of perspectives]." Fortschr
Neurol Psychiatr 72(4): 204-19.
Kelley, R. E. and A. Minagar (2004). "Memory complaints and dementia."
Prim Care 31(1): 129-48.
Khang, P., N. Weintraub, et al. (2004). "The use, benefits, and costs of
cholinesterase inhibitors for Alzheimer's dementia in long-term care: are
the data relevant and available?" J Am Med Dir Assoc 5(4):
249-55.
Kielian, T. and N. Esen (2004). "Effects of neuroinflammation on glia-glia
gap junctional intercellular communication: a perspective." Neurochem Int
45(2-3): 429-36.
Kihara, T. and S. Shimohama (2004). "Alzheimer's disease and acetylcholine
receptors." Acta Neurobiol Exp (Wars) 64(1): 99-105.
Kim, S., J. H. Seo, et al. (2004). "Alpha-synuclein, Parkinson's disease,
and Alzheimer's disease." Parkinsonism Relat Disord 10 Suppl 1:
S9-13.
Kim, S. I., H. Voshol, et al. (2004). "Neuroproteomics: expression profiling
of the brain's proteomes in health and disease." Neurochem Res
29(6):
1317-31.
King, G. D. and R. Scott Turner (2004). "Adaptor protein interactions:
modulators of amyloid precursor protein metabolism and Alzheimer's disease
risk?" Exp Neurol 185(2): 208-19.
Kismet, K., M. T. Akay, et al. (2004). "Celecoxib: a potent cyclooxygenase-2
inhibitor in cancer prevention." Cancer Detect Prev 28(2):
127-42.
Kitamura, S. (2004). "[Prognosis in Alzheimer's disease]."
Nippon Rinsho 62 Suppl: 81-5.
Klein, W. L., W. B. Stine, Jr., et al. (2004). "Small assemblies of
unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's
disease." Neurobiol Aging 25(5): 569-80.
Koch, H. J., A. Szecsey, et al. (2004). "NMDA-antagonism (memantine): an
alternative pharmacological therapeutic principle in Alzheimer's and
vascular dementia." Curr Pharm Des 10(3): 253-9.
Koudinov, A. R. and T. T. Berezov (2004). "Alzheimer's amyloid-beta (A beta)
is an essential synaptic protein, not neurotoxic junk." Acta Neurobiol
Exp (Wars) 64(1): 71-9.
Kovacs, T. (2004). "[Therapy in Alzheimer disease]."
Orv Hetil 145(17):
925-8.
Koyano, S. (2004). "[Alzheimer disease: criteria and differential
diagnosis]." Nippon Rinsho 62 Suppl: 66-71.
Kudo, T. (2004). "[Drug therapy for aged patients with Alzheimer disease]."
Seishin Shinkeigaku Zasshi 106(1): 62-7.
Kunz, M. and S. Lautenbacher (2004). "[The impact of Alzheimer's disease on
the pain processing]." Fortschr Neurol Psychiatr 72(7):
375-82.
Kurz, A., J. Diehl, et al. (2004). "[Mild cognitive disorder. Questions of
definition, diagnosis, prognosis and therapy]." Nervenarzt 75(1):
6-15.
Lahiri, D. K. (2004). "Apolipoprotein E as a target for developing new
therapeutics for Alzheimer's disease based on studies from protein, RNA, and
regulatory region of the gene." J Mol Neurosci 23(3): 225-33.
Lahiri, D. K. and N. H. Greig (2004). "Lethal weapon: amyloid beta-peptide,
role in the oxidative stress and neurodegeneration of Alzheimer's disease."
Neurobiol Aging 25(5): 581-7.
Lang, U. E., M. C. Jockers-Scherubl, et al. (2004). "State of the art of the
neurotrophin hypothesis in psychiatric disorders: implications and
limitations." J Neural Transm 111(3): 387-411.
Lansbury, P. T., Jr. (2004). "Back to the future: the 'old-fashioned' way to
new medications for neurodegeneration." Nat Med 10 Suppl:
S51-7.
Lechowski, L., B. Forette, et al. (2004). "[Diagnosis of dementia]."
Rev
Med Interne 25(5): 363-75.
Lee, H. G., G. Casadesus, et al. (2004). "Challenging the amyloid cascade
hypothesis: senile plaques and amyloid-beta as protective adaptations to
Alzheimer disease." Ann N Y Acad Sci 1019: 1-4.
Lee, H. G., X. Zhu, et al. (2004). "The role of metabotropic glutamate
receptors in Alzheimer's disease." Acta Neurobiol Exp (Wars) 64(1):
89-98.
Lee, P. E., S. S. Gill, et al. (2004). "Atypical antipsychotic drugs in the
treatment of behavioural and psychological symptoms of dementia: systematic
review." Bmj 329(7457): 75.
Leon, J., D. Acuna-Castroviejo, et al. (2004). "Melatonin and mitochondrial
function." Life Sci 75(7): 765-90.
Letenneur, L., S. Larrieu, et al. (2004). "Alcohol and tobacco consumption
as risk factors of dementia: a review of epidemiological studies." Biomed
Pharmacother 58(2): 95-9.
Lichtenthaler, S. F. and C. Haass (2004). "Amyloid at the cutting edge:
activation of alpha-secretase prevents amyloidogenesis in an Alzheimer
disease mouse model." J Clin Invest 113(10): 1384-7.
Liu, H., H. Wang, et al. (2004). "Glutathione metabolism during aging and in
Alzheimer disease." Ann N Y Acad Sci 1019: 346-9.
Lleo, A., O. Berezovska, et al. (2004). "Clinical, pathological, and
biochemical spectrum of Alzheimer disease associated with PS-1 mutations."
Am J Geriatr Psychiatry 12(2): 146-56.
Lu, K. P. (2004). "Pinning down cell signaling, cancer and Alzheimer's
disease." Trends Biochem Sci 29(4): 200-9.
Lyketsos, C. G. and H. B. Lee (2004). "Diagnosis and treatment of depression
in Alzheimer's disease. A practical update for the clinician." Dement
Geriatr Cogn Disord 17(1-2): 55-64.
MacLusky, N. J. (2004). "Estrogen and Alzheimer's disease: the
apolipoprotein connection." Endocrinology 145(7): 3062-4.
Magy, N. (2004). "[AA Amyloidosis: recent knowledges on pathophysiology]."
Rev Med Interne 25(2): 129-34.
Malouf, R. and J. Birks (2004). "Donepezil for vascular cognitive
impairment." Cochrane Database Syst Rev(1): CD004395.
Manelli, A. M., W. B. Stine, et al. (2004). "ApoE and Abeta1-42
interactions: effects of isoform and conformation on structure and
function." J Mol Neurosci 23(3): 235-46.
Mangone, C. A. (2004). "[Clinical heterogeneity of Alzheimer's disease.
Different clinical profiles can predict the progression rate]." Rev
Neurol 38(7): 675-81.
Mani, R. B. (2004). "The evaluation of disease modifying therapies in
Alzheimer's disease: a regulatory viewpoint." Stat Med 23(2):
305-14.
Marien, M. R., F. C. Colpaert, et al. (2004). "Noradrenergic mechanisms in
neurodegenerative diseases: a theory." Brain Res Brain Res Rev
45(1):
38-78.
Marino, G. and C. Lopez-Otin (2004). "Autophagy: molecular mechanisms,
physiological functions and relevance in human pathology." Cell Mol Life
Sci 61(12): 1439-54.
Marjaux, E., D. Hartmann, et al. (2004). "Presenilins in memory, Alzheimer's
disease, and therapy." Neuron 42(2): 189-92.
Marlatt, M., H. G. Lee, et al. (2004). "Sources and mechanisms of
cytoplasmic oxidative damage in Alzheimer's disease." Acta Neurobiol Exp
(Wars) 64(1): 81-7.
Maruyama, M., T. Matsui, et al. (2004). "[Diagnosing the mild cognitive
impairment stage of Alzheimer's disease]." Seishin Shinkeigaku Zasshi
106(3): 269-80.
Mathis, C. A., Y. Wang, et al. (2004). "Imaging beta-amyloid plaques and
neurofibrillary tangles in the aging human brain." Curr Pharm Des
10(13): 1469-92.
Mattson, M. P. (2004). "Pathways towards and away from Alzheimer's disease."
Nature 430(7000): 631-9.
Mattson, M. P. (2004). "Metal-catalyzed disruption of membrane protein and
lipid signaling in the pathogenesis of neurodegenerative disorders." Ann
N Y Acad Sci 1012: 37-50.
McKeith, I., J. Mintzer, et al. (2004). "Dementia with Lewy bodies."
Lancet Neurol 3(1): 19-28.
Mesulam, M. (2004). "The cholinergic lesion of Alzheimer's disease: pivotal
factor or side show?" Learn Mem 11(1): 43-9.
Mesulam, M. M. (2004). "The cholinergic innervation of the human cerebral
cortex." Prog Brain Res 145: 67-78.
Miller, L. J. and R. Chacko (2004). "The role of cholesterol and statins in
Alzheimer's disease." Ann Pharmacother 38(1): 91-8.
Milton, N. G. (2004). "Role of hydrogen peroxide in the aetiology of
Alzheimer's disease: implications for treatment." Drugs Aging 21(2):
81-100.
Miranker, A. D. (2004). "Unzipping the mysteries of amyloid fiber
formation." Proc Natl Acad Sci U S A 101(13): 4335-6.
Miyoshi, K. (2004). "[Alzheimer's disease: concept and diagnostic
criteria]." Nippon Rinsho 62 Suppl: 41-5.
Mochizuki, S. (2004). "[Neuropsychological and neuroimaging studies of
'theory of mind': a review]." No To Shinkei 56(2): 133-41.
Molinuevo, J. L., V. Garcia-Gil, et al. (2004). "Memantine: an
antiglutamatergic option for dementia." Am J Alzheimers Dis Other Demen
19(1): 10-8.
Moller, H. J., J. Barbera, et al. (2004). "Psychiatric aspects of late-life
insomnia." Sleep Med Rev 8(1): 31-45.
Montine, K. S., J. F. Quinn, et al. (2004). "Isoprostanes and related
products of lipid peroxidation in neurodegenerative diseases." Chem Phys
Lipids 128(1-2): 117-24.
Moore, R. J., R. M. Chamberlain, et al. (2004). "Apolipoprotein E and the
risk of breast cancer in African-American and non-Hispanic white women. A
review." Oncology 66(2): 79-93.
Moos, T. and E. H. Morgan (2004). "The metabolism of neuronal iron and its
pathogenic role in neurological disease: review." Ann N Y Acad Sci
1012: 14-26.
Moran, L. B. and M. B. Graeber (2004). "The facial nerve axotomy model."
Brain Res Brain Res Rev 44(2-3): 154-78.
Mori, S. (2004). "[Life environmental factors in sporadic Alzheimer's
disease]." Nippon Rinsho 62 Suppl: 52-5.
Morii, H. (2004). "[Interventions for osteoporosis in the era of high-aged
population]." Nippon Rinsho 62 Suppl 2: 9-12.
Nagata, K. (2004). "[Cigarette smoking and neurological disease]."
No To
Shinkei 56(3): 205-23.
Nagele, R. G., J. Wegiel, et al. (2004). "Contribution of glial cells to the
development of amyloid plaques in Alzheimer's disease." Neurobiol Aging
25(5): 663-74.
Nagura, H. (2004). "[Drugs for the treatment of Alzheimer's disease]."
Nippon Rinsho 62 Suppl: 76-80.
Nakamura, S. (2004). "A guideline for the treatment of dementia in Japan."
Intern Med 43(1): 18-29.
Nakase, T. and C. C. Naus (2004). "Gap junctions and neurological disorders
of the central nervous system." Biochim Biophys Acta 1662(1-2):
149-58.
Namba, Y. (2004). "[Clinical aspects of Alzheimer's disease]."
Nippon
Rinsho 62 Suppl: 61-5.
Nauck, F. and E. Klaschik (2004). "[Cannabinoids in the treatment of the
cachexia-anorexia syndrome in palliative care patients]." Schmerz
18(3): 197-202.
Nestor, P. J., P. Scheltens, et al. (2004). "Advances in the early detection
of Alzheimer's disease." Nat Med 10 Suppl: S34-41.
Newhouse, P., A. Singh, et al. (2004). "Nicotine and nicotinic receptor
involvement in neuropsychiatric disorders." Curr Top Med Chem 4(3):
267-82.
Newhouse, P. A., A. Potter, et al. (2004). "Effects of nicotinic stimulation
on cognitive performance." Curr Opin Pharmacol 4(1): 36-46.
Newton, J. L., C. E. Johns, et al. (2004). "Review article: the ageing bowel
and intolerance to aspirin." Aliment Pharmacol Ther 19(1):
39-45.
Nicoll, J. A., M. Yamada, et al. (2004). "Cerebral amyloid angiopathy plays
a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position
statement." Neurobiol Aging 25(5): 589-97; discussion 603-4.
Nikolaus, S., M. Beu, et al. (2004). "The contribution of small animal
positron emission tomography to the neurosciences--a critical evaluation."
Rev Neurosci 15(2): 131-56.
Nixon, R. A. (2004). "Niemann-Pick Type C disease and Alzheimer's disease:
the APP-endosome connection fattens up." Am J Pathol 164(3):
757-61.
Noble, M. (2004). "The possible role of myelin destruction as a
precipitating event in Alzheimer's disease." Neurobiol Aging 25(1):
25-31.
Nordberg, A. (2004). "Functional studies of cholinergic activity in normal
and Alzheimer disease states by imaging technique." Prog Brain Res
145: 301-10.
Norfray, J. F. and J. M. Provenzale (2004). "Alzheimer's disease:
neuropathologic findings and recent advances in imaging." AJR Am J
Roentgenol 182(1): 3-13.
Ojika, K. (2004). "[Differential diagnosis of and therapy for senile
dementia]." Nippon Naika Gakkai Zasshi 93(3): 515-20.
Okamoto, K. (2004). "[The coexistence of vascular dementia and Alzheimer's
disease]." Nippon Rinsho 62 Suppl: 201-5.
Okochi, M. and M. Takeda (2004). "[Familial Alzheimer's disease by
beta-amyloid protein precursor (beta APP) mutations]." Nippon Rinsho
62 Suppl: 86-9.
Olichney, J. M. and D. G. Hillert (2004). "Clinical applications of
cognitive event-related potentials in Alzheimer's disease." Phys Med
Rehabil Clin N Am 15(1): 205-33.
O'Neill, M. J., D. Bleakman, et al. (2004). "AMPA receptor potentiators for
the treatment of CNS disorders." Curr Drug Targets CNS Neurol Disord
3(3): 181-94.
Ong, W. Y. and B. Halliwell (2004). "Iron, atherosclerosis, and
neurodegeneration: a key role for cholesterol in promoting iron-dependent
oxidative damage?" Ann N Y Acad Sci 1012: 51-64.
Outeiro, T. F. and P. J. Muchowski (2004). "Molecular genetics approaches in
yeast to study amyloid diseases." J Mol Neurosci 23(1-2):
49-60.
Palotas, A., B. Penke, et al. (2004). "A chapter in the unity of
variety--calcium is the sole author?" Brain Res 1000(1-2):
57-9.
Panay, N. (2004). "Hormone replacement therapy: the way forward."
J Fam
Plann Reprod Health Care 30(1): 21-4.
Panza, F., A. D'Introno, et al. (2004). "Vascular risk and genetics of
sporadic late-onset Alzheimer's disease." J Neural Transm 111(1):
69-89.
Pastor, P. and A. M. Goate (2004). "Molecular genetics of Alzheimer's
disease." Curr Psychiatry Rep 6(2): 125-33.
Patwardhan, M. B., D. C. McCrory, et al. (2004). "Alzheimer disease:
operating characteristics of PET--a meta-analysis." Radiology 231(1):
73-80.
Peers, C., I. F. Smith, et al. (2004). "Remodelling of Ca2+ homeostasis in
type I cortical astrocytes by hypoxia: evidence for association with
Alzheimer's disease." Biol Chem 385(3-4): 285-9.
Pereira, C., E. Ferreiro, et al. (2004). "Cell degeneration induced by
amyloid-beta peptides: implications for Alzheimer's disease." J Mol
Neurosci 23(1-2): 97-104.
Pierce, A. and S. A. Small (2004). "Combining brain imaging with microarray:
isolating molecules underlying the physiologic disorders of the brain."
Neurochem Res 29(6): 1145-52.
Prasher, V. P. (2004). "Review of donepezil, rivastigmine, galantamine and
memantine for the treatment of dementia in Alzheimer's disease in adults
with Down syndrome: implications for the intellectual disability
population." Int J Geriatr Psychiatry 19(6): 509-15.
Pratico, D., J. Rokach, et al. (2004). "F2-isoprostanes as indices of lipid
peroxidation in inflammatory diseases." Chem Phys Lipids 128(1-2):
165-71.
Profenno, L. A. and P. N. Tariot (2004). "Pharmacologic management of
agitation in Alzheimer's disease." Dement Geriatr Cogn Disord 17(1-2):
65-77.
Qian, C. Y. (2004). "[Vascular dementia and vascular cognitive impairment]."
Zhongguo Yi Xue Ke Xue Yuan Xue Bao 26(2): 198-200.
Qin, Y., J. S. Qi, et al. (2004). "[Homocysteine and Alzheimer's disease]."
Sheng Li Ke Xue Jin Zhan 35(1): 66-9.
Raber, J. (2004). "Androgens, apoE, and Alzheimer's disease."
Sci Aging
Knowledge Environ 2004(11): re2.
Raber, J., Y. Huang, et al. (2004). "ApoE genotype accounts for the vast
majority of AD risk and AD pathology." Neurobiol Aging 25(5):
641-50.
Rabheru, K. (2004). "Special issues in the management of depression in older
patients." Can J Psychiatry 49(3 Suppl 1): 41S-50S.
Raina, A. K., X. Zhu, et al. (2004). "Alzheimer's disease and the cell
cycle." Acta Neurobiol Exp (Wars) 64(1): 107-12.
Rajendra, W., A. Armugam, et al. (2004). "Neuroprotection and peptide
toxins." Brain Res Brain Res Rev 45(2): 125-41.
Rasgon, N. and L. Jarvik (2004). "Insulin resistance, affective disorders,
and Alzheimer's disease: review and hypothesis." J Gerontol A Biol Sci
Med Sci 59(2): 178-83; discussion 184-92.
Rebeck, G. W. (2004). "Cholesterol efflux as a critical component of
Alzheimer's disease pathogenesis." J Mol Neurosci 23(3):
219-24.
Refolo, L. M. and H. M. Fillit (2004). "Apolipoprotein E4 as a target for
developing new therapeutics for Alzheimer's disease." J Mol Neurosci
23(3): 151-5.
Reniewska, B., M. Mulak, et al. (2004). "[Coexistence of Alzheimer's disease
with pseudoexfoliation syndrome PEX]." Klin Oczna 106(1-2):
107-9.
Richardson, D. R. (2004). "Novel chelators for central nervous system
disorders that involve alterations in the metabolism of iron and other metal
ions." Ann N Y Acad Sci 1012: 326-41.
Riederer, P., W. Danielczyk, et al. (2004). "Monoamine oxidase-B inhibition
in Alzheimer's disease." Neurotoxicology 25(1-2): 271-7.
Ringheim, G. E. and K. Conant (2004). "Neurodegenerative disease and the
neuroimmune axis (Alzheimer's and Parkinson's disease, and viral
infections)." J Neuroimmunol 147(1-2): 43-9.
Robinson, S. R., G. M. Bishop, et al. (2004). "Lessons from the AN 1792
Alzheimer vaccine: lest we forget." Neurobiol Aging 25(5):
609-15.
Robinson, S. R., C. Dobson, et al. (2004). "Challenges and directions for
the pathogen hypothesis of Alzheimer's disease." Neurobiol Aging
25(5): 629-37.
Rockwood, K. (2004). "Size of the treatment effect on cognition of
cholinesterase inhibition in Alzheimer's disease." J Neurol Neurosurg
Psychiatry 75(5): 677-85.
Rokach, J., S. Kim, et al. (2004). "Total synthesis of isoprostanes:
discovery and quantitation in biological systems." Chem Phys Lipids
128(1-2): 35-56.
Roman, G. C. and S. J. Rogers (2004). "Donepezil: a clinical review of
current and emerging indications." Expert Opin Pharmacother 5(1):
161-80.
Roman, G. C. and D. R. Royall (2004). "A diagnostic dilemma: is "Alzheimer's
dementia" Alzheimer's disease, vascular dementia, or both?" Lancet Neurol
3(3): 141.
Ross, C. A. and M. A. Poirier (2004). "Protein aggregation and
neurodegenerative disease." Nat Med 10 Suppl: S10-7.
Rossi, L., M. F. Lombardo, et al. (2004). "Mitochondrial dysfunction in
neurodegenerative diseases associated with copper imbalance." Neurochem
Res 29(3): 493-504.
Sachdev, P. (2004). "[Homocysteine and neuropsychiatric disorders]."
Rev
Bras Psiquiatr 26(1): 50-6.
Sair, H. I., P. M. Doraiswamy, et al. (2004). "In vivo amyloid imaging in
Alzheimer's disease." Neuroradiology 46(2): 93-104.
Salehi, A., J. D. Delcroix, et al. (2004). "Alzheimer's disease and NGF
signaling." J Neural Transm 111(3): 323-45.
Sanglier, I., M. Sarazin, et al. (2004). "[Tai Chi, body and cognitive
rehabilitation of Alzheimer's and related diseases]." Soins(685):
42-3.
Sauer, J., N. Tabet, et al. (2004). "Alpha lipoic acid for dementia."
Cochrane Database Syst Rev(1): CD004244.
Scatena, R. (2004). "Nitroflurbiprofen (NicOx)."
Curr Opin Investig Drugs 5(5): 551-6.
Schipper, H. M. (2004). "Heme oxygenase-1: transducer of pathological brain
iron sequestration under oxidative stress." Ann N Y Acad Sci 1012:
84-93.
Schneider, L. S. and K. S. Dagerman (2004). "Psychosis of Alzheimer's
disease: clinical characteristics and history." J Psychiatr Res
38(1):
105-11.
Schoneich, C. (2004). "Selective Cu2+/ascorbate-dependent oxidation of
alzheimer's disease beta-amyloid peptides." Ann N Y Acad Sci 1012:
164-70.
Schroecksnadel, K., B. Frick, et al. (2004). "Moderate hyperhomocysteinemia
and immune activation." Curr Pharm Biotechnol 5(1): 107-18.
Selkoe, D. J. (2004). "Alzheimer disease: mechanistic understanding predicts
novel therapies." Ann Intern Med 140(8): 627-38.
Sherratt, K., A. Thornton, et al. (2004). "Music interventions for people
with dementia: a review of the literature." Aging Ment Health 8(1):
3-12.
Shimazu, S. and I. Miklya (2004). "Pharmacological studies with endogenous
enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic
derivatives." Prog Neuropsychopharmacol Biol Psychiatry 28(3):
421-7.
Shinotoh, H., K. Fukushi, et al. (2004). "Acetylcholinesterase imaging: its
use in therapy evaluation and drug design." Curr Pharm Des 10(13):
1505-17.
Silverman, D. H. (2004). "Brain 18F-FDG PET in the diagnosis of
neurodegenerative dementias: comparison with perfusion SPECT and with
clinical evaluations lacking nuclear imaging." J Nucl Med 45(4):
594-607.
Siminoff, L. A., M. Caputo, et al. (2004). "The promise of empirical
research in the study of informed consent theory and practice." HEC Forum
16(1): 53-71.
Skjerve, A., B. Bjorvatn, et al. (2004). "Light therapy for behavioural and
psychological symptoms of dementia." Int J Geriatr Psychiatry 19(6):
516-22.
Small, D. H. (2004). "Do acetylcholinesterase inhibitors boost synaptic
scaling in Alzheimer's disease?" Trends Neurosci 27(5): 245-9.
Small, G. W. (2004). "Neuroimaging as a diagnostic tool in dementia with
Lewy bodies." Dement Geriatr Cogn Disord 17 Suppl 1: 25-31.
Smith, A. G. (2004). "Behavioral problems in dementia. Strategies for
pharmacologic and nonpharmacologic management." Postgrad Med 115(6):
47-52, 55-6.
Sobow, T., M. Flirski, et al. (2004). "Amyloid-beta and tau proteins as
biochemical markers of Alzheimer's disease." Acta Neurobiol Exp (Wars)
64(1): 53-70.
Souder, E., C. G. Rapp, et al. (2004). "Care of individuals with Alzheimer's
disease in the new millennium." Medsurg Nurs 13(1): 22-31.
Souidi, M., S. Dubrac, et al. (2004). "[Oxysterols: metabolism, biological
role and associated diseases]." Gastroenterol Clin Biol 28(3):
279-93.
Standridge, J. B. (2004). "Pharmacotherapeutic approaches to the treatment
of Alzheimer's disease." Clin Ther 26(5): 615-30.
Steiger, J. L. and S. J. Russek (2004). "GABAA receptors: building the
bridge between subunit mRNAs, their promoters, and cognate transcription
factors." Pharmacol Ther 101(3): 259-81.
Sternon, J. and J. C. Bier (2004). "[Memantine (Ebixa), glutaminergic
modulator]." Rev Med Brux 25(2): 93-7.
Streit, W. J. (2004). "Microglia and Alzheimer's disease pathogenesis."
J
Neurosci Res 77(1): 1-8.
Sultzer, D. L. (2004). "Psychosis and antipsychotic medications in
Alzheimer's disease: clinical management and research perspectives." Dement Geriatr Cogn Disord
17(1-2): 78-90.
Suzuki, Y. and Y. Kuroiwa (2004). "[Vitamin E]."
Nippon Rinsho 62
Suppl: 376-8.
Szekely, C. A., J. E. Thorne, et al. (2004). "Nonsteroidal anti-inflammatory
drugs for the prevention of Alzheimer's disease: a systematic review."
Neuroepidemiology 23(4): 159-69.
Tabira, T. (2004). "[A molecular genetic overview of familial dementing
disorders]." Nippon Rinsho 62 Suppl 4: 206-13.
Tabira, T. (2004). "[Alzheimer's disease due to presenilin mutations]."
Nippon Rinsho 62 Suppl: 90-4.
Tabira, T. (2004). "[Development of prevention and treatment of Alzheimer's
disease: a minireview]." Nippon Ronen Igakkai Zasshi 41(1):
23-5.
Takao, M. and T. Amano (2004). "[Vascular factor of Alzheimer disease]."
Nippon Rinsho 62 Suppl: 56-60.
Takashima, A. and D. Chui (2004). "[Animal model for Alzheimer's disease]."
Nippon Rinsho 62 Suppl 4: 240-7.
Takeda, M. (2004). "[Role of psychiatrists in long-term care for the aged]."
Seishin Shinkeigaku Zasshi 106(1): 53-5.
Takuma, K., A. Baba, et al. (2004). "Astrocyte apoptosis: implications for
neuroprotection." Prog Neurobiol 72(2): 111-27.
Tanimukai, S. (2004). "[Role of psychiatrists in early diagnosis of senile
dementia]." Seishin Shinkeigaku Zasshi 106(1): 56-61.
Tariot, P. N., L. A. Profenno, et al. (2004). "Efficacy of atypical
antipsychotics in elderly patients with dementia." J Clin Psychiatry
65 Suppl 11: 11-5.
Ten, S. and N. Maclaren (2004). "Insulin resistance syndrome in children."
J Clin Endocrinol Metab 89(6): 2526-39.
Teter, B. (2004). "ApoE-dependent plasticity in Alzheimer's disease."
J
Mol Neurosci 23(3): 167-79.
Timins, J. K. (2004). "Current issues in hormone replacement therapy."
N
J Med 101(3): 21-7.
Tooyama, I., A. Matsuo, et al. (2004). "[Genetic risk factors for
Alzheimer's disease]." Nippon Rinsho 62 Suppl: 46-51.
Touhy, T. A. (2004). "Dementia, personhood, and nursing: learning from a
nursing situation." Nurs Sci Q 17(1): 43-9.
Trzesniewska, K., M. Brzyska, et al. (2004). "Neurodegenerative aspects of
protein aggregation." Acta Neurobiol Exp (Wars) 64(1): 41-52.
Tsai, L. H., M. S. Lee, et al. (2004). "Cdk5, a therapeutic target for
Alzheimer's disease?" Biochim Biophys Acta 1697(1-2): 137-42.
Tuszynski, M. H. and A. Blesch (2004). "Nerve growth factor: from animal
models of cholinergic neuronal degeneration to gene therapy in Alzheimer's
disease." Prog Brain Res 146: 441-9.
van Leeuwen, F. W. (2004). "Neuropeptide research discloses part of the
secrets of Alzheimer's disease neuropathogenesis: state of the art 2004."
Neurosci Lett 361(1-3): 124-7.
Vassar, R. (2004). "BACE1: the beta-secretase enzyme in Alzheimer's
disease." J Mol Neurosci 23(1-2): 105-14.
Vina, J., A. Lloret, et al. (2004). "Molecular bases of the treatment of
Alzheimer's disease with antioxidants: prevention of oxidative stress."
Mol Aspects Med 25(1-2): 117-23.
Voisin, T., E. Reynish, et al. (2004). "What are the treatment options for
patients with severe Alzheimer's disease?" CNS Drugs 18(9):
575-83.
Volpicelli, L. A. and A. I. Levey (2004). "Muscarinic acetylcholine receptor
subtypes in cerebral cortex and hippocampus." Prog Brain Res 145:
59-66.
von Bartheld, C. S. (2004). "Axonal transport and neuronal transcytosis of
trophic factors, tracers, and pathogens." J Neurobiol 58(2):
295-314.
Voytko, M. L. and G. P. Tinkler (2004). "Cognitive function and its neural
mechanisms in nonhuman primate models of aging, Alzheimer disease, and
menopause." Front Biosci 9: 1899-914.
Wagman, A. S., K. W. Johnson, et al. (2004). "Discovery and development of
GSK3 inhibitors for the treatment of type 2 diabetes." Curr Pharm Des
10(10): 1105-37.
Wang, L. H., C. G. Besirli, et al. (2004). "Mixed-lineage kinases: a target
for the prevention of neurodegeneration." Annu Rev Pharmacol Toxicol
44: 451-74.
Wang, Y. P., J. F. Song, et al. (2004). "[CDK5 and neurodegenerative
disease]." Sheng Li Ke Xue Jin Zhan 35(1): 45-8.
Webber, K. M., R. Bowen, et al. (2004). "Gonadotropins and Alzheimer's
disease: the link between estrogen replacement therapy and neuroprotection."
Acta Neurobiol Exp (Wars) 64(1): 113-8.
Weinstock, M. and S. Shoham (2004). "Rat models of dementia based on
reductions in regional glucose metabolism, cerebral blood flow and
cytochrome oxidase activity." J Neural Transm 111(3): 347-66.
Werner, N. and M. Bohm (2004). "[Treatment with ACE inhibitors until the end
of life? Cardiovascular protective mechanisms during blockade of the
renin-angiotensin system]." Dtsch Med Wochenschr 129(27):
1513-8.
Whitehouse, P. J. (2004). "Paying attention to acetylcholine: the key to
wisdom and quality of life?" Prog Brain Res 145: 311-7.
Wilkinson, D. G., P. T. Francis, et al. (2004). "Cholinesterase inhibitors
used in the treatment of Alzheimer's disease: the relationship between
pharmacological effects and clinical efficacy." Drugs Aging 21(7):
453-78.
Wilton, T. (2004). "Cyclooxygenase-2 inhibitors: do they have a role in
emergency department prescribing?" Emerg Med Australas 16(1):
65-73.
Wimo, A. (2004). "Cost effectiveness of cholinesterase inhibitors in the
treatment of Alzheimer's disease: a review with methodological
considerations." Drugs Aging 21(5): 279-95.
Wirthner, D., J. Cornuz, et al. (2004). "[Preventing of postmenopausal
osteoporosis by hormone replacement therapy? Is the risk acceptable?]."
Schweiz Rundsch Med Prax 93(9): 315-20.
Wu, G., Y. Z. Fang, et al. (2004). "Glutathione metabolism and its
implications for health." J Nutr 134(3): 489-92.
Wynn, Z. J. and J. L. Cummings (2004). "Cholinesterase inhibitor therapies
and neuropsychiatric manifestations of Alzheimer's disease." Dement
Geriatr Cogn Disord 17(1-2): 100-8.
Wyttenbach, A. (2004). "Role of heat shock proteins during polyglutamine
neurodegeneration: mechanisms and hypothesis." J Mol Neurosci 23(1-2):
69-96.
Xu, B. G. and X. Wu (2004). "[Advances in molecular biology and clinical
study of amyloid precursor protein for Alzheimer's disease]." Zhongguo Yi
Xue Ke Xue Yuan Xue Bao 26(2): 201-9.
Yakel, J. L. and Z. Shao (2004). "Functional and molecular characterization
of neuronal nicotinic ACh receptors in rat hippocampal interneurons."
Prog Brain Res 145: 95-107.
Yamada, M. and H. Yasuhara (2004). "Clinical pharmacology of MAO inhibitors:
safety and future." Neurotoxicology 25(1-2): 215-21.
Yamaguchi, S. (2004). "[Preventive effects of anti-inflammatory drugs(non
steroidal anti-inflammatory drugs) on Alzheimer disease]." Nippon Rinsho
62 Suppl: 479-83.
Yamamoto, Y. and R. B. Gaynor (2004). "IkappaB kinases: key regulators of
the NF-kappaB pathway." Trends Biochem Sci 29(2): 72-9.
Yamamoto, Y. and S. Sakoda (2004). "[Presenile dementia with motor neuron
disease]." Nippon Rinsho 62 Suppl: 158-61.
Yao, P. J. (2004). "Synaptic frailty and clathrin-mediated synaptic vesicle
trafficking in Alzheimer's disease." Trends Neurosci 27(1):
24-9.
Yatomi, N. (2004). "[Prevention of senile dementia]."
Seishin Shinkeigaku
Zasshi 106(1): 68-72.
Yazawa, K. (2004). "[Importance of "health foods", EPA and DHA, for
preventive medicine]." Rinsho Byori 52(3): 249-53.
Zamrini, E., S. De Santi, et al. (2004). "Imaging is superior to cognitive
testing for early diagnosis of Alzheimer's disease." Neurobiol Aging
25(5): 685-91.
Zekanowski, C., D. Religa, et al. (2004). "Genetic aspects of Alzheimer's
disease." Acta Neurobiol Exp (Wars) 64(1): 19-31.
Zhang, X. (2004). "Cholinergic activity and amyloid precursor protein
processing in aging and Alzheimer's disease." Curr Drug Targets CNS
Neurol Disord 3(2): 137-52.
Zhu, B. T. (2004). "CNS dopamine oxidation and catechol-O-methyltransferase:
importance in the etiology, pharmacotherapy, and dietary prevention of
Parkinson's disease." Int J Mol Med 13(3): 343-53.
Zhu, X., A. K. Raina, et al. (2004). "Oxidative stress signalling in
Alzheimer's disease." Brain Res 1000(1-2): 32-9.
Zhu, X., A. K. Raina, et al. (2004). "Alzheimer's disease: the two-hit
hypothesis." Lancet Neurol 3(4): 219-26.
Zlokovic, B. V. (2004). "Clearing amyloid through the blood-brain barrier."
J Neurochem 89(4): 807-11.
Back to top |
AD Review References: 2004